andrewkaretas, Author at Allogene

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

Post author:andrewkaretas
Post published:August 8, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

August 13, 2025 5:00 PM EDT : The Allogene Therapeutics Second Quarter 2025 Conference Call

Post author:andrewkaretas
Post published:August 6, 2025
Post category:Events

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Post author:andrewkaretas
Post published:August 6, 2025
Post category:Latest News

Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…

8-K: Report of unscheduled material events or corporate event

Post author:andrewkaretas
Post published:August 1, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

August 1, 2025 11:00 AM EDT : Allogene Investor Call

Post author:andrewkaretas
Post published:August 1, 2025
Post category:Events

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Post author:andrewkaretas
Post published:August 1, 2025
Post category:Latest News

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee , and in Consultation with the FDA Following an ALLO-647-Related Death in the…